Ovarian cancer drug developer's stock cut in half after it files for FDA approval

The Needham biotech’s application for approval in the U.S. wasn’t greeted positively by investors, likely because it would be for a smaller patient population than hoped.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *